Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Stock analysts at Cantor Fitzgerald reduced their FY2017 earnings estimates for shares of Aurinia Pharmaceuticals in a research note issued on Monday. Cantor Fitzgerald analyst E. Piros now expects that the company will earn ($1.35) per share for the year, down from their prior estimate of ($1.27). Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.97) EPS.
ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP)” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/22/fy2017-eps-estimates-for-aurinia-pharmaceuticals-inc-cut-by-cantor-fitzgerald-aup.html.
Separately, Seaport Global Securities reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.